obesity drugs

In a recent announcement, Eli Lilly and Co (NYSE:LLY) has projected a significant revenue increase for 2024, driven by the demand for its diabetes and obesity drugs. What Happened: The pharmaceutical giant anticipates a 20% rise in sales, propelling its revenues to over $40 billion, reported the...

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless...

Stocks in the food and beverage industry experienced their most challenging week since May 2022, further extending the declines seen in the preceding weeks. The First Trust Nasdaq Food & Beverage ETF (NYSE:FTXG) plummeted by over 5% this week, marking its third consecutive week of losses and...